



Immune Design  
 Investor Relations Department  
 Immune Design Corp. Attn:  
 Accounts Payab  
 601 Gateway Blvd. Suite 250  
 South San Francisco, CA 94080  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

**NASDAQ: IMDZ**

Last Trade:	3.78
Trade Time:	2:52 PM ET Dec 12, 2017
Change:	0.08 <span style="color: green;">↑</span> (+2.027%)
Day Range	3.65 - 3.83
52-Week Range	3.55 - 13.05
Volume	428,785

Stock information is provided by eSignal,  
 stock charts provided by EDGAR Online.  
 Stock data is delayed approximately 20  
 minutes.

**Company Profile**

Immune Design is a clinical stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™.

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Dec 10, 2017  
[Combination of G100 with KEYTRUDA \(pembrolizumab\) Triggers Robust Systemic Responses in Follicular NHL Patients](#)
- Nov 13, 2017  
[Immune Design to Present at Jefferies 2017 London Healthcare Conference](#)
- Nov 7, 2017  
[Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candidates](#)
- Nov 1, 2017  
[Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- Oct 27, 2017  
[Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update](#)

**Financials** [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 7, 2017  
[Annual Report \(10-K\)](#)
- Apr 26, 2017  
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017  
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017  
[Quarterly Report \(10-Q\)](#)